trial · primary record
relacorilant
Cushing Syndrome
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 125 |
| Primary completion | 2026-12 |
| Primary endpoint | Long-term safety of relacorilant |
| Registry ID | NCT03604198 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:39.241Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03604198
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Relacorilant · approval
- relacorilant · compound